Our Team
The Founders
The founder Lynne Lim and cofounder Gan Chee Wee have worked together on CLiKX for the last decade.
®
Dr Lynne Lim
Lynne is a Senior Consultant Ear Nose Throat Surgeon, and Adj Assoc Professor and Visiting Consultant to the National University Health System Singapore. Her research fellowship and clinical sub-specialisation were in Paediatric ENT, Hearing, and Ear Reconstruction at Cincinnati Children Hospital Medical Centre, Stanford Medical Centre, University of Virginia Medical Centre and Nagata Plastic and Ear Reconstruction Clinic, Japan. She did her MPH at Harvard School of Public Health and is passionate about improving health outcomes for patients. Lynne was Vice- Dean at School of Medicine, National University Singapore, and Vice Chairman Medical Affairs at National University Hospital. She has pioneered several firsts in hearing implants surgery in Asia and Singapore, and was primary investigator for over SGD 14 million in competitive research grants. Lynne was founding director for the MSc Audiology program NUS, and for the Centre for Hearing Speech and Balance at NUHS. She set up the roving Minivan Hearing Service to improve access to hearing services for elderly heart-landers. She especially enjoyed the many opportunities to visit and teach in the APAC and Middle East neighbouring countries. Since 2014, Lynne has been in private ENT practice. She continues to be passionate about innovating to meet the real needs of patients. (www.drlynnelim.com)
Mr Gan Chee Wee
Chee Wee is currently the Chief Technical Officer with NousQ, overseeing the product realization process to translate innovative concepts into clinically and commercially viable products. Chee Wee graduated with B.Eng and M.Eng in Chemical and Biomolecular Engineering from the National University of Singapore, specializing in Biomolecular Engineering. His research interests are on drug delivery and MedTech / Biomedical innovation. He has led overall project grants management and the technical design, development and pre-clinical testing including various biological and cadaver models. Chee Wee has had extensive training and knowledge in quality management system and medical device regulatory affairs and has Engineering Technical Consultancy experience in other medical product development.
Chief Operating Officer
Mr Huang Junquan
Junquan started his career in the biomedical industry in 2006 as part of the human islet isolation program at St. Vincent’s Institute in Australia. Upon returning to Singapore, Junquan worked in Health Sciences Authority (HSA) and Agency for Science, Technology and Research (A*STAR). In 2011, Junquan joined Biolidics Ltd (formerly known as Clearbridge Biomedics Pte Ltd) where he held several positions that culminated in his appointment as Chief Operating Officer. He was instrumental in leading the company's product development and commercialization of cancer diagnostic devices. He also assisted the company’s IPO in the Singapore Stock Exchange in 2018. He joined INEX Innovate in 2020, a molecular diagnostic company before he founded his own medical device consultancy firm. Junquan obtained a Bachelor of Biomedical Science and Bachelor of Science (Degree with Honours) from the University of Melbourne, Australia.
Senior Vice President, Strategy & Business Development
Mr Ricardo Villanueva
Ricardo is a finance and mergers & acquisitions (M&A”) professional. Prior to joining NousQ, he was the Head of M&A and Strategic Planning for IHH Healthcare. During his tenure, IHH Healthcare more than doubled the number of hospitals in its portfolio from 35 hospitals to become one of the world’s largest integrated private healthcare providers with 80 hospitals in 10 countries. Ricardo graduated in Economics and Finance with a BCA (Hons) from the Victoria University of Wellington. He also has an MBA from the University of Chicago’s Booth School of Business.
President
Ms Sarah Sachinis
Sarah is President of NousQ, based in the USA, with 17 years of U.S and international commercial healthcare experience. Sarah started her career in the U.K. in pharmaceutical sales at Astrazeneca, moving into medical device sales and marketing for Smith and Nephew in Europe. Sarah has spent the last 8 years of her career working for start-up medical devices leading multiple business functions, specializing in developing and bringing disruptive technology into new markets across the world. Most recently Sarah worked as the Chief Commercial Officer at Trice Medical, successfully developing and launching orthopedic surgical devices that increase healthcare efficiency, moving procedures into the clinic as well as reducing operating room time. Sarah has a Bachelor of Science Degree in Psychology from the University of Surrey.
Consultants (Finance & Strategy)
Mr David Ng
David brings together 30+ years of broad industry and international experience as a finance leader. His corporate work encompasses a focus on intellectual property and technology translation which has seen him work internationally with start-up founders across biotechnology, media and PaaS as a consultant and CFO. His Ph.D. (SMU) focused on start-ups and he now blends ongoing corporate engagements as a fractional CFO with academic research, mentoring and teaching at universities.
Mr Tan Woei Ren
Woei Ren brings together 20+ years of experience in Finance gained through working at a Big 4 accounting firm, MNCs and start-ups as a Chartered Accountant and MBA graduate. He has held various senior finance positions at MNCs in the consumer electronics, aquaculture, and pharmaceutical / biotechnology sector. His business development work has seen him lead cross functional teams in supporting M&A and due diligence projects. Woei Ren’s more recent interests encompass the financial planning and the valuation of start-ups and SMEs. He also dedicates time to do community volunteer work on a regular basis.
Board of Directors
Mr Quek How Jiang
How Jiang is the CEO of Genedant Capital Pte Ltd, a Singapore-based investment company focused on the emerging science and technology sectors. He was previously an Executive Director at Octagon Advisors, a Singapore-founded specialist risk management consultancy to financial institutions. Prior to joining Octagon Advisors, How Jiang was a First Vice President in Singapore’s United Overseas Bank responsible for the business unit focused on the Bank’s key mass affluent retail customer segment, and concurrently its Investment Services Unit, tasked with developing UOB’s entire suite of wealth management products. Before joining UOB, How Jiang was the Senior Manager for Institutional Asset Management at Dresdner Asset Management (now part of Allianz Global Investors) based in its Singapore and Frankfurt units. How Jiang started his career at the Monetary Authority of Singapore (MAS), where he was responsible for the development of the Singapore financial centre. He was also the Staff Assistant to the Managing Director of MAS and the MAS Press Officer during his tenure. How Jiang is also a negotiation skills trainer, and has delivered courses to staff of MNCs in the region.
How Jiang was awarded the Overseas Undergraduate Scholarship by the Monetary Authority of Singapore for study at the London School of Economics and Political Science, where he graduated with a First Class Honours degree in Monetary Economics. He has passed all 3 levels of the Chartered Financial Analyst examinations.
Dr Pang Hau Yun
Dr. Nathan Pang has had 5 years of clinical experience and 20 years of leadership experience in the biopharmaceutical industry, which he first joined as Medical Director in Glaxo Wellcome Taiwan from 1998. In 2001 he served with Novartis Asia-Pacific as Regional Marketing Director, and later appointed in 2002 as Regional Head for Oncology Business Unit, Asia Pacific. Nathan has significant direct experience in China having spent nearly 15 years residing and working there. In 2006, Nathan was CEO of Sandoz China, the Generics Division of Novartis Group. From 2010 to 2014, Nathan served as the President for China, Sasteria. From 2014 to 2018 he served as GM China heading Sanofi Pasteur, the vaccines division of the Sanofi Group. After which he had his third tour of duty in China, appointed from Feb 2019 as CEO of AffaMed Therapeutics, a PE invested start up. Currently he is SVP, Asia Head for BioNTech.
Dr. Nathan Pang is a registered Medical Physician in Singapore; holds a dual EMBA from France’s INSEAD and China’s Tsinghua University, Bachelor of Law from University of London, as well as Bachelor of Medicine & Surgery from National University of Singapore.
We will continue to welcome more experts to our boards soon.